Safety and Efficacy of Fingolimod in Iranian Patients with Relapsing-remitting Multiple Sclerosis

INTRODUCTION: Fingolimod is the first confirmed oral immune-modulator to treat Relapsing-Remitting Multiple Sclerosis (RRMS). This study aimed to investigate the safety and efficacy of fingolimod therapy in Iranian patients with RRMS. METHODS: In our trial, 50 patients resistant to conventional inte...

Descripción completa

Detalles Bibliográficos
Autores principales: Yavari, Fatemeh, Oliazadeh, Pardis, Radfar, Meisam, Foroughipour, Mohsen, Nikkhah, Karim, Heidari Bakavoli, Alireza, Saeidi, Morteza
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Iranian Neuroscience Society 2021
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8672667/
https://www.ncbi.nlm.nih.gov/pubmed/34925720
http://dx.doi.org/10.32598/bcn.12.2.1681.1

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8672667/
https://www.ncbi.nlm.nih.gov/pubmed/34925720
http://dx.doi.org/10.32598/bcn.12.2.1681.1

Ejemplares similares